P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY - T. Facon; S. K. Kumar; T. Plesner; P. Moreau; N. Bahlis; H. Goldschmidt; M. O’Dwyer; A. Perrot; C. P. Venner; K. Weisel; J. R. Mace; N. Raje; et al. (HemaSphere, 2022)